Comparative Pharmacology
Head-to-head clinical analysis: KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE versus TOLECTIN 600.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE versus TOLECTIN 600.
KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE vs TOLECTIN 600
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Phenylephrine is a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Ophthalmic: 1 drop of the combination (ketorolac tromethamine 0.45% and phenylephrine hydrochloride 1%) into the operative eye three times daily, beginning 1 day prior to surgery and continuing on the day of surgery and for 2 weeks postoperatively.
600 mg orally three times daily; maximum 1800 mg/day.
None Documented
None Documented
Ketorolac: 2.4-8.6 hours (mean 5.3 hours) in young adults; prolonged in elderly (up to 13.9 hours) and renal impairment. Phenylephrine: 2-3 hours.
Terminal elimination half-life is approximately 5 hours (range 4-6 hours) in healthy adults; prolonged in renal impairment.
Ketorolac: ~92% renal (60% as unchanged drug, 32% as metabolites), 6% fecal. Phenylephrine: primarily renal as metabolites (sulfate conjugates) with <1% unchanged.
Renal: approximately 90% as metabolites and conjugates; biliary/fecal: minor (less than 10%)
Category D/X
Category C
NSAID
NSAID